Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

The Motley Fool September 18, 2009 Brian Orelli	Up, Down, Up. Is This Stock a Home Run or Not? Shares of Arena Pharmaceuticals have been on a roller coaster after word that the company would release data for its obesity drug.
The Motley Fool July 16, 2010 Brian Orelli	Why VIVUS Is 57% Thinner In a move that slashed the pharmaceutical's shares, Food and Drug Administration advisory committee recommended that the agency not approve their obesity drug Qnexa.
The Motley Fool June 25, 2010 Brian Orelli	Mark Your Calendars: Obesity Drugs Take Center Stage Orexigen Therapeutics has been given an FDA advisory committee meeting date, completing the dates for the trio of obesity drugs up for review.
The Motley Fool November 23, 2009 Brian Orelli	The Side Effect of Developing Obesity Drugs The FDA is fickle when it comes to weight-loss drugs.
Chemistry World September 17, 2010 Andrew Turley	Obesity drugs strive for US approval Could 2010 yet be the year of the obesity drug? At first glance the signs are promising. Regulators in the US will soon decide whether to allow three new contenders onto this attractive market.
The Motley Fool December 12, 2008 Brian Orelli	The Skinny on the Latest Drug Trial VIVUS' obesity treatment data looks good, but will its drug be a marketing success?
The Motley Fool December 31, 2010 Brian Orelli	2010 FDA Approvals and a Look Ahead Recent history can help us handicap FDA decisions.
The Motley Fool July 16, 2010 Luke Timmerman	Vivus Obesity Drug Shot Down by FDA Panel Vivus suffered a setback today at an important meeting for the future of obesity drug development, with implications for Arena Pharmaceuticals and Orexigen Therapeutics.
The Motley Fool July 16, 2010 Tom Hughes	Lessons Learned About the Outlook for New Obesity Drug Approval The recent FDA advisory committee meeting on Vivus' weight loss pill proved to us, once again, how incredibly difficult it is to successfully develop and register new drugs for obesity.
The Motley Fool April 5, 2011 Brian Orelli	Obese Expectations Trump Great Data Sorry VIVUS and Orexigen, you're still not going to get your drugs approved quickly.
The Motley Fool September 17, 2010 Brian Orelli	Thanks for Nothing, Fen-Phen Arena gets knocked down despite a relatively clean side-effect profile.
The Motley Fool July 13, 2010 Brian Orelli	A Triple Delight: 3 Stocks All Up More Than 10% What's good for the obese goose is good for the gander when it comes to new drug treatments for losing weight.
The Motley Fool February 8, 2011 Esterhuizen & Sellitti	Battle of the Bulge: Biotech Takes on Obesity and Diabetes Will recent advances in pharmaceutical research revolutionize the weight loss industry? It's still early days, but here are some of the stocks to watch.
The Motley Fool July 14, 2010 Luke Timmerman	Vivus Faces Turning Point Tomorrow Thursday's the big day. All eyes will be on Vivus and the FDA's decision on their new obesity drug
Chemistry World June 28, 2012 Patrick Walter	FDA green lights new obesity drug Lorcaserin, which has been developed by US-based Arena Pharmaceuticals, in conjunction with Japan's Eisai, is the first obesity prescription medicine approved for 13 years.
The Motley Fool January 4, 2012 Brian Orelli	This Biotech's Obese To-Do List Is Done Arena resubmits lorcaserin for FDA approval.
Wired October 2006	Trial and Error At one time the following drugs had high hopes, but time proved the side effects were overwhelming: Amphetamines, Phen-Fen, Sibutramine, Orlistat, and Rimonabant.
The Motley Fool December 22, 2010 Brian Orelli	Arena Charges On It seems Fool readers were a little more optimistic about the timing of Arena Pharmaceuticals' resubmission of its obesity drug to the Food and Drug Administration than the company is.
The Motley Fool September 2, 2010 Luke Timmerman	Orexigen Nabs $1B Deal With Takeda to Market Obesity Drug, Shares Climb San Diego-based Orexigen Therapeutics has found a partner to help it compete in the growing market for drugs to combat obesity, Japan-based Takeda Pharmaceutical.
Managed Care January 2006 Martin Sipkoff	Skeptics Abound as Demand Grows For Obesity Treatments Changes in reimbursement patterns for obesity drugs will take several years. Lifestyle changes remain the first approach.
The Motley Fool May 4, 2011 Brian Orelli	VIVUS Unveils Its Obesity Plans Investors are getting fat on the news that VIVUS has a plan, and a backup plan, to get its obesity drug Qnexa on the market.
American Family Physician October 15, 2005 Huntington & Yuan	Topiramate (Topamax) for Migraine Prevention Topiramate is more effective than placebo for migraine prevention. Its effectiveness appears to be similar to that of other antiepileptic drugs and beta blockers.
The Motley Fool March 30, 2009 Brian Orelli	Hopes Fall Short for Arena Pharmaceuticals Arena Pharmaceuticals' obesity drug lorcaserin doesn't look like it's doing enough to be a marketing success -- and the results might not even be enough to get it past the Food and Drug Administration.
The Motley Fool June 3, 2011 Brian Orelli	FDA Bullies Obesity Drugmakers It's been clear for some time that the Food and Drug Administration isn't particularly fond of obesity drugs. Now it's just being a bully.
The Motley Fool October 11, 2010 Brian Orelli	What Meridia's Demise Means for Arena, VIVUS, and Orexigen Safety first ... and second ... and third...
The Motley Fool September 21, 2010 Brian Orelli	Double-Digit Weight Loss, Double-Digit Share Increase Vivus is down, but apparently not out.
The Motley Fool December 22, 2011 Brian Orelli	VIVUS' Obese Pink Elephant Qnexa data can't be ignored.
The Motley Fool September 21, 2011 Brian Orelli	Obesity-Drug Makers Stop Getting Bullied The drugs are still relative long shots being developed by companies that may have to raise more cash between now and an approval.
The Motley Fool May 27, 2008 Brian Orelli	Livin' la Vivus Loca Irrational Exuberance for Vivus' Lead Drug Candidate?
American Family Physician June 1, 2001 James M. Lyznicki	Obesity: Assessment and Management in Primary Care Obesity is a complex, multifactorial condition in which excess body fat may put a person at health risk. National data indicate that the prevalence of obesity in the United States is increasing in children and adults...
BusinessWeek September 1, 2009 Catherine Arnst	Opportunities in the Obesity Epidemic Drugmakers are ratcheting up research into treatments for gout and other ills that plague the overweight.
The Motley Fool October 19, 2010 Brian Orelli	Why the FDA Won't Approve Lorcaserin and Qnexa (Yet) Obesity drugs get their day in front of the agency.
The Motley Fool April 5, 2005 Stephen D. Simpson	Can Obesity Fatten Your Wallet? Obesity is an increasingly serious problem, but could it also be a major opportunity for health-care companies? Investors should spend a little due diligence on the pharmaceutical side.
The Motley Fool May 27, 2011 Brian Orelli	Don't Believe the Obesity Hype Meta-analysis data isn't going to help Arena Pharmaceuticals' obesity drug.
Managed Care December 2004 Jack McCain	The Weight Debate, Continued This article presents the views of people who indulge in what many regard as health care heresy. They challenge the conventional wisdom that millions of Americans need to lose tons of weight, fast, to stave off diabetes, heart disease, cancer.
The Motley Fool January 9, 2012 Brian Orelli	Don't Believe This Company's Warning VIVUS' news is great news.
American Family Physician December 15, 2003 John Epling	Is Fluoxetine an Effective Therapy for Weight Loss in Obese Patients? Fluoxetine (Prozac) use may result in an average, short-term weight loss of up to 3.3 kg (7 lb, 4 oz) in obese patients, but the long-term effects and maintenance of weight loss after discontinuation of the drug have not been well studied.
The Motley Fool October 25, 2010 Brian Orelli	Arena's Boring News The Food and Drug Administration turned down Arena Pharmaceuticals' obesity drug, lorcaserin. Tell us something we didn't know.
The Motley Fool September 16, 2011 Brian Orelli	A Shrinking Obesity Market VIVUS figures some sales are better than none for its obesity drug Qnexa.
The Motley Fool June 3, 2011 Luke Timmerman	Orexigen, Facing High Hurdle at FDA, Puts Obesity Drug Development on Hold The close attention paid to safety makes this drug difficult to get right.
The Motley Fool April 30, 2007 Mike Havrilla	VIVUS Revives Investor Interest New drugs with huge markets could keep shares of VIVUS on their upward trajectory.
The Motley Fool September 9, 2009 Brian Orelli	Weight Down. Stock Price Up. Really Up. Positive phase 3 trials will do that for VIVUS' anti-obesity drug, Qnexa
The Motley Fool September 16, 2010 Brian Orelli	Abbott's Product Line May Get Thinner Not that it needs the obesity drug.
Chemistry World January 12, 2007 John Bonner	First Drug for Fat Dogs Pfizer has been granted a licence by the US FDA to market the world's first medical treatment for canine obesity. Slentrol is a selective microsomal triglyceride transfer protein inhibitor, blocking the assembly and release of lipids from the gut wall into the bloodstream.
The Motley Fool March 2, 2011 Susmita Chatterjee	How to Capitalize on the Obesity Epidemic Does broader use of Allergan's Lap-Band signify competition for others?
American Family Physician March 15, 2003 McInnis et al.	Counseling for Physical Activity in Overweight and Obese Patients An estimated 97 million adults in the United States, or more than six out of 10 men and women, are overweight or obese. The role of physicians and other health care professionals is associated with greater efforts to help patients adopt healthy lifestyle habits related to diet and exercise.
The Motley Fool September 14, 2010 Luke Timmerman	Arena Obesity Drug Effective by "Slim Margin"; Shares Tumble The market is reacting negatively to news about the company's weight-loss drug.
The Motley Fool March 31, 2011 Brian Orelli	Drug Warning Labels: The Good, Bad, and Ugly Once a drug is approved, investors can't fall asleep and ignore FDA announcements about drugs. They come in different varieties, but warnings tend to be of the bad and ugly variety more often than the good.
BusinessWeek December 27, 2004 Kerry Capell	The End Of Obesity As We Know It Sanofi-Aventis' Acomplia takes aim at two of the great maladies of the century. But approval isn't a slam dunk.
The Motley Fool April 1, 2008 Brian Lawler	VIVUS' New Old Drugs The small company finds plenty of help as it tries to get its anti-obesity drug to market.